Navigation Links
Biomarker associated with poor outcome in aggressive childhood cancer
Date:4/6/2009

Results from a new study identify a biomarker that may be useful for predicting the outcome of treatment for neuroblastoma, the most common cancer in young children. The research, published by Cell Press in the April 7th issue of the journal Cancer Cell, also provides new information about the molecular signals that are involved in the progression of this often devastating pediatric cancer.

Retinoic acid (RA) is a metabolite of Vitamin A that has important influences over the processes of growth and differentiation. RA mediates gene expression by interacting with retinoic acid receptors (RARs) that, in the presence of RA, switch from repressing target genes to activating them. Because many targets of RA induce differentiation or cell death, RA is used as a therapeutic agent in many cancers, including neuroblastoma.

"Many neuroblastoma patients exhibit aggressive tumors with poor clinical outcome," explains senior study author Dr. Rene Bernards from The Netherlands Cancer Institute. "While some of these aggressive tumors exhibit increased expression of the MYCN oncogene, little is known about the other genetic factors that control neuroblastoma progression." Dr. Bernards and colleagues performed a genome-wide RNA interference screen to search for additional components of the RA signaling pathway that might be linked to neuroblastoma.

The researchers identified ZNF423 as a critical cofactor of RA-induced differentiation. Reduced expression of ZNF423 was led to a growth advantage and resistance to RA differentiation in neuroblastoma cells while increased expression of ZNF423 led to growth inhibition and enhanced differentiation. The researchers went on to show that ZNF423 interacts with the RAR?/RXR? nuclear receptor that is necessary for activation in response to retinoids.

Importantly, low expression levels of ZNF423 were associated with poor disease outcome in neuroblastoma patients, suggesting that the gene might be useful as a prognostic biomarker. "Expression levels of ZNF423 could significantly affect responses to both endogenous and pharmacological concentrations of RA in cancer patients, which may in turn influence the outcome of neuroblastoma," offers Dr. Bernards. "Therefore, ZNF423 may be a useful biomarker for predicting responses to RA-based therapies, which are increasingly being used to treat neuroblastoma."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Naturally fluorescent molecules may serve as cancer biomarker
2. Wayne State University Scientists ID New Biomarker for Prostate Cancer
3. Scientists ID New Biomarker for Prostate Cancer
4. Penn Medicine pathologists pioneer biomarker test to diagnose or rule out Alzheimers disease
5. Dr. Arun Sreekumar lectures on new candidate biomarker at Annual EAU Congress
6. Biomarkers detected for Chikungunya fever
7. Biomarker predicts disease recurrence in colorectal cancer
8. Major study on DiagnoCures GCC biomarker published in Jama
9. Researchers ID Biomarker for Fatal Prostate Cancer
10. Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer
11. MDS Analytical Technologies Laser Capture Microdissection Helps Facilitate Discovery of Potential New Colon-Cancer Biomarker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... A four alarm fire ... site and threatened numerous homes and businesses nearby, causing some 700 individuals to ... Los Angeles Area consulting firm Fire Protection Group, Inc. notes that the report ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn skin care product, ... of the leading causes of long term skin conditions, including cancer. In ...
(Date:7/24/2017)... ... July 24, 2017 , ... The 2017 ... MD. This year's theme focuses on the new ISO/IEC 17025 standards. This marks ... integrity in testing and calibration will be changed. , As an exhibitor, ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... received the prestigious StorErotica “Consumer’s Choice” Award, for favorite sex toy. Created in ... 11th annual StorErotica Awards to be consumer voted. The Magic Wand Rechargeable won ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... Medicine Clinical Vitiligo Hospital" was set up, and the awarding ceremony was held ... Chinese medicine, the head of the army's health system, and national Chinese medicine ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)...  Centurion Medical Products, a leader in medical product innovation and ... removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of a ... pain while preventing unneeded emergency department admission due to severe fecal ...
(Date:7/11/2017)... July 11, 2017 Zymo Research Corp., also known as ,The ... quantify biological aging in a precise manner using the myDNAge ™ ... , a professor of human genetics and biostatistics at the David ... Public Health , Zymo Research,s proprietary DNAge ™ technology is used ... ...
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
Breaking Medicine Technology: